spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

West Announces Official Opening of Expanded Kiefernweg Campus and New Center of Excellence for Innovation and Technology in Eschweiler, Germany

Eschweiler, Germany — November 9, 2017

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today officially opened the Company’s recently expanded Kiefernweg Campus in Eschweiler, Germany, which includes a new global center of excellence for the research and development of pharmaceutical packaging components and systems for injectable medicines.

The new 6,500 square meter campus includes two new office buildings, the original Kiefernweg office, and an Innovation & Technology center of excellence, which was created to consolidate and align West’s global R&D offices that previously operated in several different sites across Germany. This expansion will enable West to meet the growing demand for high-quality injectable drug packaging and delivery systems from pharmaceutical and biotechnology companies operating in Europe and around the world.

“This is an exciting time in the biopharmaceutical industry with new, innovative therapies being introduced to the market that address significant unmet medical needs,” said Reinhard Waeben, Vice President, Packaging Components, R&D at West. “Yet it is also a time of great challenge, with increasing demands on drug manufacturers to ensure both the quality and speed with which those products are delivered to patients. We will be working within our Innovation & Technology center to bring forward the latest advancements in primary packaging for injectable medicines to help address these customer challenges.”

The Kiefernweg campus currently employs approximately 185 people in a number of global functions, including: product development, engineering, manufacturing, quality, supply chain, procurement, sales, marketing, customer service, IT, Human Resources and other administrative functions. West also maintains two manufacturing plants nearby in Eschweiler and Stolberg, which are part of the Company’s global manufacturing network.

“With our state-of-the-art Innovation & Technology center here at Kiefernweg, and two global manufacturing plants close by in Eschweiler and Stolberg, West is well positioned to provide our customers with cutting-edge containment and delivery solutions for the future that can be scaled up quickly and efficiently,” said Heino Lennartz, Managing Director at West in Germany.

West is also a long-time supporter of the local community in which it operates. As part of the ribbon-cutting ceremony, West presented two local non-profit organizations with donations, on top of local employee-raised contributions that were collected as part of the Company’s grassroots employee giving program. One of the organizations, Fortschritt Staedteregion Aachen e. V., provides conductive therapy for children and young adults with conditions that affect motor function, such as multiple sclerosis, strokes and Parkinson’s disease. The other organization, Zwischen Uns e. V., offers a place of employment to young adults with mental and physical disabilities. Both organizations have been the recipient of West employee donations and volunteer time for the past several years.

For more information on West and current job openings in the region, please visit http://www.westpharma.com/careers.

Forward-Looking Statements
Certain forward-looking statements are included in this release. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that West's business will achieve any level of commercial success. These forward-looking statements involve a number of risks and uncertainties. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2016. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

About West
West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world’s pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West’s 2016 net sales of $1.5 billion reflect the daily use of approximately 112 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.
###
West, the diamond logo, and By your side for a healthier world™ are registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Countdown to the UK’s leading production line event begins

In light of Nick Peters’, author of the Annual Manufacturing report 2018, comment that “UK manufacturing has come a long way in recent years, as we have seen from their stellar performance in 2017,” it’s no surprise that the PPMA Show is gearing up for its biggest show to date when it returns to the NEC, Birmingham, between 25-27 September 2018.
More info >>


White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
More info >>

Industry Events

RDD Asia 2018

14-15 November 2018, Grand Hyatt Kochi, Kerala, India

A must-attend meeting for pulmonary and nasal researchers, inhaled product developers and vendors active in this important pharmaceutical niche.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement